Uncategorized
August 31, 2026 by Dawn Lam
Introduction Nucleic Acid Therapeutics (NATs), including antisense oligonucleotides (ASOs), splice-switching oligos, siRNAs and their conjugates act inside cells in tissue, not in plasma, so interpreting their pharmacology depends on measuring tissue concentrations of the intact drug in the presence of chain-shortened metabolites. This review covers the hybridization assay formats in current use, the chemistry that […]
Read more »
Tagged
August 6, 2026 by Dawn Lam
Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), act through base pairing between a short sequence and a target transcript. Although sequences can be selected that perfectly match only the intended target, partial complementarity to other transcripts can cause off-target effects (Figure 1). These hybridization-dependent off-target effects have been well established for […]
February 10, 2026 by Dawn Lam
Over the past decade, China has implemented sweeping reforms that dramatically shortened drug development cycles and streamlined clinical trial approvals. A major driver of this acceleration is China’s long-term, innovation-focused policy agenda. Under the 14th and 15th Five‑Year Plans, the government emphasized biological manufacturing, precision medicine, and innovation‑led growth, signaling a shift from infrastructure expansion […]
December 4, 2025 by Dawn Lam
Next Generation Sequencing (NGS) Grade From synthesis, deprotection and downstream processing, every step is optimized to reduce cross-contamination and mutations to yield oligos with the lowest possible error rates. Therapeutic Grade Whether your therapeutic lead is an aptamer, ASO, siRNA, sgRNA or an Antibody– or Peptide–Oligo Conjugate, we provide the highest levels of purity and […]
Get technical content, promotions, and upcoming event news — straight to your inbox.
